HLB bioStep Co.,Ltd. (KOSDAQ:278650)
South Korea
· Delayed Price · Currency is KRW 1,221.00
-11.00 (-0.89%)
At close: Mar 6, 2026
HLB bioStep Revenue
HLB bioStep had revenue of 23.97B KRW in the quarter ending September 30, 2025, with 29.33% growth. This brings the company's revenue in the last twelve months to 71.47B, up 25.92% year-over-year. In the year 2024, HLB bioStep had annual revenue of 58.17B with 10.14% growth.
Revenue (ttm)
71.47B
Revenue Growth
+25.92%
P/S Ratio
1.43
Revenue / Employee
486.16M
Employees
147
Market Cap
102.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.17B | 5.35B | 10.14% |
| Dec 31, 2023 | 52.81B | -33.46B | -38.79% |
| Dec 31, 2022 | 86.28B | 21.87B | 33.96% |
| Dec 31, 2021 | 64.40B | 5.88B | 10.05% |
| Dec 31, 2020 | 58.52B | 12.48B | 27.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DreamCIS | 62.06B |
| P&K Skin Research Center | 22.13B |
| C&R Research | 63.97B |
| WOOJUNG BIO | 37.12B |
| DT&CRO CO. | 44.36B |
| SLS BIO | 5.47B |
| BioInfra | 21.92B |
| Hyundai ADM Bio | 9.74B |